Aiming to realize our business philosophy “VISION 2015”

In order to realize Astellas Pharma's business philosophy, “Contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products, VISION 2015 has been settled to show how Astellas must look in the year 2015, and the guidelines and strategies necessary to achieve this.

Positioning of VISION 2015
VISION 2015 shows precisely how our Business Philosophy can be put into practice.

Future environment surrounding the pharmaceutical industry

Complexity and segmentation of the pharmaceutical market will be increased due to the followings: progress of policies to control health expenditures, decrease in market growthrate due to the patent expiration of top-line products and promotion of use of generics, and growth of specialty market where high unmet medical needs exist. Thus, it is thought in the future market not only scale but also a variety of competitive advantage will exist.

Business model of Astellas

Astellas is aiming a construction of its business model, a “Global Category Leader” (“GCL”.) A GCL is in several ‘categories’ where high unmet medical needs exist and a high degree of expertise is required. A GCL shows higher competitiveness by providing value-added products ‘globally’ and takes over the position of ‘leader’ in a category. Astellas will seek to enhance enterprise value in a sustainable manner through heading maximization of value-added for all people seeking health, and creating a business model, a “Global Category Leader” not just seeking for enlargement of sales scale.

We do not merely aim for expanding the company's sales, but we intend to continuously increase our corporate value by establishing this GCL business model and by “maximizing added value to people who wish to become healthy,” including our patients.

Strategy to realize GCL

In order to realize being a GCL, Astellas will promote sustainable reinforcement of current products, solid progress of current pipeline, further reinforcement of global sales and marketing activities, and in-licensing and business development activities aggressively. Moreover, Astellas settled six categories, including urology, inflammation/immunology, infectious diseases (virus), neurology/sharp pains, diabetes, and cancer, as its most important R&D categories with concern of unmet medical needs, market potential, and research potential. Astellas aims to expand categories in a sustainable manner by aggressive investment in these categories and improvement of product creation.

Three systems to fulfill and realize “VISION 2015.”

1.Human resources management system

Astellas has identified human resources development as its most important issue, and is tackling this with competitive investment.

2.Management control system

Astellas will build a system to achieve an appropriate level of management control to allow it to realize faster and better decision-making based on the required information.

3.CSR-based management

Astellas will clarify its corporate social responsibility and promote the CSR-based management to establish a system to fulfill it.

Astellas' Three Systems

---